All In Biotech

Drug Trial Radar · NCT05110157

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 442 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

442

Actual

Start

Nov 29, 2021

Primary completion

Feb 4, 2025

Study completion Feb 18, 2025

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

Conditions

  • Schizophrenia

Interventions

  • PlaceboDrug

    Oral capsules

  • ValbenazineDrug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to Week 10Time frame: Baseline to week 10

Locations

87 sites in 4 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Phoenix, Arizona

  • Neurocrine Clinical Site

    Rogers, Arkansas

  • Neurocrine Clinical Site

    Anaheim, California

  • Neurocrine Clinical Site

    Bellflower, California

  • Neurocrine Clinical Site

    Culver City, California

  • Neurocrine Clinical Site

    Garden Grove, California

  • Neurocrine Clinical Site

    Lemon Grove, California

  • Neurocrine Clinical Site

    Long Beach, California

  • Neurocrine Clinical Site

    Oceanside, California

  • Neurocrine Clinical Site

    Pico Rivera, California

  • Neurocrine Clinical Site

    Riverside, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    San Jose, California

  • Neurocrine Clinical Site

    Santa Ana, California

  • Neurocrine Clinical Site

    Stanford, California

  • Neurocrine Clinical Site

    Torrance, California

  • Neurocrine Clinical Site

    Aventura, Florida

  • Neurocrine Clinical Site

    Coral Gables, Florida

  • Neurocrine Clinical Site

    Daytona Beach, Florida

  • Neurocrine Clinical Site

    Hialeah, Florida

  • Neurocrine Clinical Site

    Hialeah, Florida

  • Neurocrine Clinical Site

    Hialeah, Florida

  • Neurocrine Clinical Site

    Miami, Florida

  • Neurocrine Clinical Site

    Miami, Florida

  • Neurocrine Clinical Site

    Miami, Florida

  • Neurocrine Clinical Site

    Miami Lakes, Florida

  • Neurocrine Clinical Site

    Okeechobee, Florida

  • Neurocrine Clinical Site

    Tampa, Florida

  • Neurocrine Clinical Site

    West Palm Beach, Florida

  • Neurocrine Clinical Site

    Atlanta, Georgia

  • Neurocrine Clinical Site

    Evanston, Illinois

  • Neurocrine Clinical Site

    Springfield, Illinois

  • Neurocrine Clinical Site

    Grand Rapids, Michigan

  • Neurocrine Clinical Site

    St Louis, Missouri

  • Neurocrine Clinical Site

    St Louis, Missouri

  • Neurocrine Clinical Site

    Lincoln, Nebraska

  • Neurocrine Clinical Site

    Las Vegas, Nevada

  • Neurocrine Clinical Site

    Cedarhurst, New York

  • Neurocrine Clinical Sites

    Glen Oaks, New York

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.